title: Defect of interleukin-2 production and T cell proliferation in atopic patients: restoring ability of the CD28-mediated activation pathway.
abstract: We previously reported that T lymphocytes of atopic patients displayed a defect in CD2- and CD3-mediated pathways of cell activation; that defect relied on impairment of interleukin 2 (IL-2) production (Romano, M. F., Valerio, G., Turco, M. C., Spadaro, G., Venuta, S., and Formisono, S., Cell. Immunol. 139, 91, 1992). We have subsequently analyzed T cell response to anti-CD2, -CD3, or -CD28 monoclonal antibodies (mAb) in 40 atopic individuals, including patients subjected to immunotherapy. In the latter group T cell response to anti-CD2 mAbs was normal, while IL-2 production and proliferative response in T lymphocytes stimulated via CD3 was still impaired. Costimulation with anti-CD28 mAb rescued both IL-2 production and proliferative response in all tested patients. Response to CD28-mediated stimulation was more pronounced in atopic than that in normal individuals. Our results indicated that CD28 had a major role in T cell proliferation of atopic patients and provided a model for analyzing CD3/CD28 interactions in regulation of IL-2 gene expression.
authors.affiliation: Dipartimento di Biologia e Patologia Cellulare e Molecolare, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italia.
authors.forename: M F
authors.initials: MF
authors.lastname: Romano
authors.forename: M C
authors.initials: MC
authors.lastname: Turco
authors.forename: A
authors.initials: A
authors.lastname: Stanziola
authors.forename: P C
authors.initials: PC
authors.lastname: Giarrusso
authors.forename: A
authors.initials: A
authors.lastname: Petrella
authors.forename: P
authors.initials: P
authors.lastname: Tassone
authors.forename: R
authors.initials: R
authors.lastname: van Lier
authors.forename: S
authors.initials: S
authors.lastname: Venuta
authors.forename: S
authors.initials: S
authors.lastname: Formisano
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D018801:CD2 Antigens; D018106:CD28 Antigens; D017252:CD3 Complex / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D007167:Immunotherapy; D007376:Interleukin-2 / Q000096:biosynthesis*; D008213:Lymphocyte Activation; D008875:Middle Aged; D011971:Receptors, Immunologic / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; D017252:CD3 Complex; D007376:Interleukin-2; D011971:Receptors, Immunologic